AbilityPharma is a biopharmaceutical company developing new first-in-class candidates to treat cancer. We are focused on autophagy as a new therapeutic strategy to induce cell death selectively in cancer cells. Based on this novel mechanism of action, we are generating a portfolio of new drugs targeting oncological unmet needs.
ABTL0812 has completed the recruitment in a phase 2b double-blind placebo-controlled clinical trial in 140 patients with metastatic pancreatic cancer in USA, Spain, France and Israel.
ABTL0812 has completed the recruitment in a phase 2b double-blind placebo-controlled clinical trial in 140 patients with metastatic pancreatic cancer in USA, Spain, France and Israel.
Media Center
16.07.2024
AGC Pharma Chemicals and AbilityPharma work together to produce innovative treatment for pancreatic cancer + info
11.03.2024
AbilityPharma Announces € 7 Million Financing Round to Advance Development of its Clinical Phase 2b Autophagy Inducer ABTL0812 in Metastatic Pancreatic Cancer + info
29.12.2020
The Chinese SciClone becomes shareholder of Ability Pharma with € 2.5 million + info